Report

The Value of Innovation in Oncology

Recognizing Emerging Benefits Over Time White Paper

PhRMA May 27, 2015

A new white paper by Boston Healthcare Associates examines how innovative medicines are driving significant progress in the fight against cancer. Though initial approval by the U.S. Food and Drug Administration is a tremendous milestone, ongoing research and accumulation of knowledge reveals benefits that were not able to be recognized at that time. Through use in combinations, earlier in the disease progression, use with biomarkers, and even in other disease indications, additional value emerges over time.

Download